The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE OR NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on that assumption, some 20 institutions representing different sectors of the health care system launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across multiple stakeholders, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient. By combining the data from those tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans.
PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

- **Education**: To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers about how the field can make the health system more effective and efficient by targeting better treatments to only those patients who will benefit.

- **Advocacy**: To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.

- **Evidence Development**: To encourage the swifter adoption of personalized medicine by health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

— Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

• Public Policy Committee
  • Patient Advocacy Organization Working Group
  • Pharma and Diagnostics Working Group
  • Intellectual Property Working Group

• Science Policy Committee
  • Clinical Integration Working Group
  • Value Assessment Working Group
  • Information Management Working Group

• Pharmacogenomics Working Group

MEMBER BENEFITS

Contact 2,000+
leaders in personalized medicine via PMC’s member database

Interact with 200+
thought leaders from Congress, FDA, CMS and the private sector at member meetings and events

Save 40%
on registration for the Annual Personalized Medicine Conference

Attend Member Meetings and Events at no charge

Discounted Subscription Offers for outlets including GenomeWeb, STAT News, and The Journal of Precision Medicine

Receive Copies of PMC publications and reports
PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES
Invitae
Laboratory Corporation of America (LabCorp)
Quest Diagnostics

DIAGNOSTIC COMPANIES
Adaptive Biotechnologies
Admera Health
Agenda NV
Agilent Technologies
Alacris Theranostics GmbH
Almac Diagnostics
Asuragen
Caprion Proteomics
Caris Life Sciences
CareDx, Inc.
Circulogene
Clarinet Health
Cofactor Genomics
Dacieutics
Exact Sciences
Foundation Medicine, Inc.
GeneCentric Therapeutics
Grail
Guardant Health
MolecularMD
Myriad Genetics
NanoString Technologies
Olaris Therapeutics
Personalis
QIAGEN, Inc.
Roche Diagnostics
RxGenomix
Scipher Medicine
Siemens Healthcare Diagnostics, Inc.
SomaLogic, Inc.
Thrive
Zionexa US Corporation

EMERGING BIOTECH/PHARMACEUTICAL COMPANIES
Aperiomics
Freenome
Immatics US
Legend Biotech
PAREXEL
Regeneron
Tango Therapeutics
WuXi NextCode

HEALTH INSURANCE COMPANIES
Harvard Pilgrim
Health Care

INDUSTRY/TRADE ASSOCIATIONS
American Clinical Laboratory Association
BIO (Biotechnology Innovation Organization)
Biocom
PHRMA

IT/INFORMATICS COMPANIES
2bPrecise
Change Healthcare
DNAnexus
Flatiron Health
GNS Healthcare
M2Gen
Medidata
P4-ML
PierianDx
Salutary, Inc.
Syapse
Translational Software
XIFIN, Inc.

LARGE BIOTECH/PHARMACEUTICAL COMPANIES
AbbVie
Amgen, Inc.
Astellas Pharma Global Development
AstraZeneca Pharmaceuticals
Bausch Health Companies
Bayer
Biogen
Bristol-Myers Squibb
Eli Lilly and Company
Genentech, Inc.
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Takeda Pharmaceuticals, Inc.

NUTRITION, HEALTH & WELLNESS COMPANIES
Preventive Partners

PATIENT ADVOCACY GROUPS
Accelerated Cure Project for Multiple Sclerosis
Alliance for Aging Research
Alzheimer’s Foundation of America
Asian & Pacific Islander American Health Forum
Bulgarian Association for Personalized Medicine
Canadian Organization for Rare Disorders
Clearrity Foundation
Colorectal Cancer Alliance
CureDuchenne
Emily’s Entourage
EveryLife Foundation For Rare Diseases
Fight Colorectal Cancer
Friends of Cancer Research
GO2 Foundation for Lung Cancer
Global Liver Institute
HealthyWomen
International Cancer Advocacy Network (“ICAN”)
LUNGevity Foundation
Multiple Myeloma Research Foundation
National Alliance Against Disparities in Patient Health
National Alliance for Hispanic Health
National Health Council
National Patient Advocate Foundation
OpenOme
Team Trevor

PERSONALIZED MEDICINE SERVICE PROVIDERS
Coriell Life Sciences
Genome Medical Helix
Intervention Insights
Michael J. Bauer, M.D., & Associates, Inc.
Sema4
Tempus

RESEARCH, EDUCATION & CLINICAL CARE INSTITUTIONS
American Association for Cancer Research (AACR)
American Medical Association (AMA)
Arizona State University Association for Molecular Pathology (AMP)
Baylor Health Care System Precision Medicine Institute
Brown University
Business Finland
Cancer Treatment Centers of America
Cello Health BioConsulting
College of American Pathologists
Colorado Center for Personalized Medicine
CommonSpirit Health
Coriell Institute for Medical Research
CREATE Health Translational Cancer Centre, Lund University
Dasman Diabetes Institute
Duke Center for Research on Personalized Health Care
Essentia Institute of Rural Health
European Infrastructure for Translational Medicine
Genome British Columbia
Genome Canada
Harvard Business School
Hospital Albert Einstein
Instituto de Salud Carlos III
Intermountain Healthcare
Johns Hopkins Individualized Health
King Faisal Specialist Hospital and Research Centre
MaineHealth Accountable Care Organization
Manchester University School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson – Institute for Personalized Cancer Therapy
MITRE Corporation
Moffitt Cancer Center
National Pharmaceutical Council
Nicklaus Children’s Hospital Research Institute
North Carolina Biotechnology Center
NorthShore University Hospital System
Precision Health Initiative at Cedars-Sinai
Qatar Biobank
Quebec Network for Personalized Health Care
Sanford Imagenetics, Sanford Health
Shenandoah University
Swedish Cancer Institute
The Christ Hospital
The Jackson Laboratory
Thomas Jefferson University
Translational Genomics Research Institute
UC Davis Mouse Biology Program
University of Alabama, Birmingham
University of California, San Francisco (UCSF)
University of Pennsylvania Health System
University of Rochester
University of South Florida
Morsani College of Medicine
Vanderbilt University Medical Center
West Cancer Center

RESEARCH TOOL COMPANIES
Illumina, Inc.
Thermo Fisher Scientific

STRATEGIC PARTNERS
Alva10
Arnold & Porter
Artisan Healthcare Consulting
Bioscience Valuation
BSV GmbH
Blue Latitude Health
Boston Healthcare Associates
Bradford Power
Bruce Quinn Associates
Cambridge Healthtech Institute
Center for Individual Opportunity
ConText
ConvergeHEALTH by Deloitte
Defined Health
Dr. Alana Maria Lelo
EdgeTech Law, LLP
EY Parthenon
Foley & Lardner, LLP
Foley Hoag, LLP
Genome Creative
Goldbug Strategies, LLC
Health Advances, LLC
Hogan Lovells, LLP
Innovation Horizons
Innovation Policy Solutions
Jane Binger, Ed.D.

As of January 2020
DUES STRUCTURE
As of January 2020

Large Public Corporation $29,000
Small Public Corporation $14,500
Trade Association (based on revenues)
Private Corporation >50 FTEs $5,775
Professional Society $5,775
Private Corporation <50 FTEs $3,500
Strategic Partner $2,900
Research, Education & Clinical Care Institutions $2,900
Sole Proprietor $1,150
Patient Advocacy Group $500

Visit pmc.portal.membersuite.com to join the Coalition.

For more information, contact Kayla Smith, Director, Membership & Development, at ksmith@personalizedmedicinecoalition.org or 202-589-0070.
STAFF

Edward Abrahams, Ph.D.
President

Cynthia A. Bens
Senior Vice President,
Public Policy

Daryl Pritchard, Ph.D.
Senior Vice President,
Science Policy

Faswilla Sampson, M.S.
Vice President, Operations

Christopher J. Wells, M.P.A.
Vice President, Public Affairs

Kayla Smith
Director, Membership &
Development

David L. Davenport
Manager, Public Policy; Secretary
to the Board

Lindsay Stephens
Senior Operations Coordinator

BOARD OF DIRECTORS

Jay G. Wohlgemuth, M.D.
Board Chair
Quest Diagnostics

William S. Dalton, Ph.D., M.D.
Board Vice Chair
M2Gen

Mark P. Stevenson, M.B.A.
Board Treasurer
Thermo Fisher Scientific

Michael Pellini, M.D., M.B.A.
Board Secretary
Section 32

Bonnie J. Addario
GO2 Foundation for Lung Cancer

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for
Translational Medicine (EATRIS)

Randy Burkholder
PhRMA

Stephen L. Eck, M.D., Ph.D.
Immatics US

Lori Frank, Ph.D.
Alzheimer’s Foundation of America

Brad Gray
NanoString Technologies

Kris Joshi, Ph.D.
Change Healthcare

Anne-Marie Martin, Ph.D.
Novartis

Howard L. McLeod, Pharm.D.
J. Brian Munroe
Bausch Health Companies

Lincoln Nadauld, M.D., Ph.D.
Intermountain Healthcare

Kimberly J. Popovits
Hakan Sakul, Ph.D.
Pfizer, Inc.

Michael S. Sherman, M.D.,
M.B.A., M.S.
Harvard Pilgrim Health Care

Apostolia M. Tsimeridou,
M.D., Ph.D.
MD Anderson Cancer Center

Michael Vasconcelles, M.D.
Flatiron Health

Werner Verbiest
Johnson & Johnson